Solid Biosciences Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Solid Biosciences Inc. (Nasdaq: SLDB) develops precision genetic medicines, primarily gene therapies, targeting rare neuromuscular and cardiac diseases. Founded in 2013 and headquartered in Charlestown, Massachusetts, the company advances a diversified pipeline that includes SGT-003, a next-generation AAV gene therapy in Phase 1/2 trials (INSPIRE and IMPACT studies) for Duchenne muscular dystrophy utilizing the proprietary AAV-SLB101 capsid; SGT-212, a dual-route administration gene therapy for Friedreich's ataxia that has received FDA Fast Track designation and IND clearance; SGT-501 for RYR2- and CASQ2-mediated catecholaminergic polymorphic ventricular tachycardia; SGT-601 for TNNT2-mediated dilated cardiomyopathy; SGT-401 for BAG3-mediated dilated cardiomyopathy; SGT-701 for RBM20-mediated dilated cardiomyopathy; and additional undisclosed cardiac programs in collaboration with Mayo Clinic, alongside platform technologies such as neuromuscular and cardiac capsid libraries, novel promoters, dual gene expression systems, and immunomodulation techniques. Solid Biosciences operates principally in the United States, serving patients with high-unmet-need genetic disorders through research, preclinical development, and clinical-stage gene transfer candidates. In recent developments, the company broadened its pipeline over the last two years to encompass multiple neuromuscular and cardiac indications beyond Duchenne muscular dystrophy, advanced SGT-003 into clinical trials with its optimized capsid, opened a second IND for the industry-first dual-route SGT-212 program, continued building next-generation capsid libraries with selections anticipated in Q4 2025, and licensed its AAV-SLB101 capsid to 15 academic and corporate partners; earlier, in 2022, it acquired AavantiBio to create a combined entity focused on neuromuscular and cardiac rare diseases, supported by a $75 million private placement financing.
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (NASDAQ:SLDB) Stock Price Up 5.5% on Analyst Upgrade
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of “Moderate Buy” by Brokerages
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial